Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data

• Váldodahkkit: Philip S. Watson (Dahkki), Patricia Novy (Dahkki), Rafik Bekkat-Berkani (Dahkki), Florence Strubbe (Dahkki), Angelika Banzhoff (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2019-04-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Introduction: Meningococcal disease has an incidence peak spread over several years during adolescence and young adulthood in the United States. Meningococcal serogroup B (MenB) vaccines have been introduced relatively recently and may help protect individuals in these age groups. Currently there is...